Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

US-China Trade Agreement Specifies Patent Protection Rules for Drugs

publication date: Jan 16, 2020

The Phase I trade agreement between the US and China contains several important rules that are important for novel biopharma companies, with China agreeing to new rules for resolving pharmaceutical patent disputes, patent term extension and counterfeit medicines. China will warn patent holders when a generic pharma seeks regulatory approval for generic or biosimilar versions of a patent-protected drug, and to do so while the patent holder has time to respond. The agreement also contains six pages of rules for resolving disputes. The agreement does not, however, specify how long novel drugs will be protected by patents. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China